Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 91 pages | ID: S21F80D10309EN
Global Markets Direct

Abstracts

Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia (SCA) - Drugs In Development, 2022, provides an overview of the Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline landscape.

Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia (SCA) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 13 and 8 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 4 and 2 molecules, respectively.

Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Spinocerebellar Ataxia (SCA) - Overview
Spinocerebellar Ataxia (SCA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
Spinocerebellar Ataxia (SCA) - Drug Profiles
Spinocerebellar Ataxia (SCA) - Dormant Projects
Spinocerebellar Ataxia (SCA) - Discontinued Products
Spinocerebellar Ataxia (SCA) - Product Development Milestones
Featured News & Press Releases
May 23, 2022: Biohaven provides update on phase 3 clinical trial evaluating troriluzole for spinocerebellar ataxia (SCA)
Nov 08, 2021: Seelos Therapeutics announces FDA acceptance of investigational new drug application and grant of fast track designation for SLS-005 (IV Trehalose) for the treatment of Spinocerebellar Ataxia
Oct 07, 2021: Blade Therapeutics announces publication of preclinical evidence supporting neuroprotective effects of proprietary calpain inhibitor in a rare inherited neurodegenerative disease
Jun 29, 2021: US FDA grants VICO therapeutics orphan-drug designation for VO659, an investigational therapy for spinocerebellar ataxia
Apr 13, 2021: Biohaven announces presentations on troriluzole at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Mar 29, 2021: SM Life Sciences submits IND for spinal cerebellar ataxia treatment
Feb 10, 2021: European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an investigational herapy for spinocerebellar ataxia
Dec 21, 2020: Seelos Therapeutics announces issuance of a patent for Trehalose (SLS-005) in Israel
Nov 11, 2020: Biohaven Pharmaceuticals inaugural partner Of National Ataxia Foundation's drug development collaborative
Jan 23, 2020: Cadent Therapeutics announces FDA acceptance of IND application for CAD-1883 for Spinocerebellar Ataxia (SCA)
Jan 22, 2020: Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry
Dec 04, 2019: Seelos Therapeutics receives notice of allowance for an additional US patent for Trehalose (SLS-005)
May 29, 2019: Cadent Therapeutics announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia
May 07, 2019: Biohaven advances late stage clinical program and novel targets from neuroinnovation platform
May 03, 2019: Biohaven announces presentation of Troriluzole in phase IIb/III trial at American Academy Of Neurology (AAN) 2019 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Anima Biotech Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Annji Pharmaceutical Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Biogen Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by BioXcel Corp, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Blade Therapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Celavie Biosciences LLC, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Corestem Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Dystrogen Therapeutics SA, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Enzerna Biosciences LLC, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Everfront Biotech Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Exicure Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Gene Therapy Research Institution Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by IntraBio Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Locanabio Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Novartis AG, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by PTC Therapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Q-State Biosciences Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Sclnow Biotechnology Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Seelos Therapeutics, Inc., 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Steminent Biotherapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Triplet Therapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Vico Therapeutics BV, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Wave Life Sciences Ltd, 2022
Spinocerebellar Ataxia (SCA) - Dormant Projects, 2022
Spinocerebellar Ataxia (SCA) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022